Brief: Transgene Reports On Combination Trial Of TG4010, Chemotherapy And Nivolumab

Transgene SA

12/12/2019 17:15

Dec 12 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE REPORTS ON THE COMBINATION TRIAL OF TG4010,
CHEMOTHERAPY AND NIVOLUMAB IN NON-SMALL CELL LUNG CANCER
    * TRANSGENE SA - STUDY FAILS TO MEET PRIMARY ENDPOINT OF
OVERALL
RESPONSE RATE IN PATIENTS WHOSE TUMORS EXPRESS LOW-TO-NO PD-L1
    * TRANSGENE SA - ADDITIONAL DATA ANALYSES ARE STILL ONGOING
AND
COMPLETE STUDY RESULTS WILL BE PRESENTED AT AN UPCOMING
SCIENTIFIC CONFERENCE.
    * TRANSGENE SA - WITH FUNDING UNTIL 2022 OUR STRATEGY
REMAINS
CLEAR AND UNCHANGED
    * TRANSGENE SA - PHASE 2 COMBINATION TRIAL OF TG4001 IN
HPV-POSITIVE CANCERS IS RECRUITING WELL
    * TRANSGENE SA - PHASE 2 COMBINATION TRIAL OF TG4001 IN
HPV-POSITIVE CANCERS: NEXT CLINICAL READOUT PLANNED IN H1 2020
    * TRANSGENE SA - CLINICAL SITES HAVE BEEN INITIATED AND
FIRST TWO
TRIALS EVALUATING TG4050 WILL SOON BE ENROLLING PATIENTS
    * TRANSGENE SA - WE EXPECT TO SUBMIT A CLINICAL TRIAL
APPLICATION
IN FIRST HALF OF 2020 FOR BT-001

Source text for Eikon:  ID:nBw5J1RdFa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))